Regenerative Medical Technology Group Inc.
For the period ended Dec 31, 2024. Filed Apr 15, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Apr 15, 2025
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Dated April 15, 2025 | REGERATIVE MEDICAL TECHNOLOGY GROUP | |
|---|---|---|
| By: | /s/ David Christensen | |
| David Christensen | ||
| President, Chief Executive Officer, Chief Financial Officer, Secretary and Director | ||
In accordance with the requirements of the Securities Act of 1934, this Annual Report was signed by the following person in the capacities and on the date stated:
| Name | Title | Date |
|---|---|---|
| /s/ David Christensen | President, Chief Executive Officer, Chief | April 15, 2025 |
| David Christensen | Financial Officer, Secretary and Director |
TABLE OF CONTENTS
| Page | |
| Report of Independent Registered Public Accounting Firm | F-2 |
|---|---|
| Consolidated Balance Sheets as of December 31, 2024 and 2023 | F-3 |
| Consolidated Statements of Operations for the Years Ended December 31, 2024 and 2023 | F-4 |
| Consolidated Statements of Stockholders’ Deficit for the Years Ended December 31, 2024 and 2023 | F-5 - F-6 |
| Consolidated Statements of Cash Flows for the Years Ended December 31, 2024 and 2023 | F-7 |
| Notes to Consolidated Financial Statements | F-8 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.